{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:01:17Z","timestamp":1777676477990,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ipsen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015\u20132017) or aboBoNT-A (Cohort 2; 2017\u20132019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs. Adverse events were recorded for Cohort 2. Cohort 1 included 60 patients (mean [standard deviation] dose, 206.0 [98.8] U); Cohort 2 included 54 patients (753.7 [457.3] U). Mean (95% confidence interval) GAS-T scores for Cohorts 1 and 2 were 43.1 (39.3\u201346.9) and 47.8 (43.7\u201351.9) at Week 6, and 43.2 and 44.3 at Week 12, respectively. In both cohorts most patients were satisfied with treatment. At Week 12, QoL had not changed in Cohort 1 but had improved in Cohort 2 (EQ-5D VAS, \u22125). Mean estimated per-patient costs (in 2021) for Cohorts 1 and 2 were \u00a3315.56 and \u00a3249.25, respectively, at Week 6, and \u00a3343.20 and \u00a3273.21, respectively, at Week 12. Fifteen non\u2013treatment-related serious adverse events and two deaths were recorded. These data may warrant a larger prospective study powered to compare outcomes of aboBoNT-A and onaBoNT-A.<\/jats:p>","DOI":"10.3390\/toxins15090532","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T10:09:49Z","timestamp":1693390189000},"page":"532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity"],"prefix":"10.3390","volume":"15","author":[{"given":"Clive","family":"Bezzina","sequence":"first","affiliation":[{"name":"North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-on-Trent ST6 7AG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Degtiar","sequence":"additional","affiliation":[{"name":"Ipsen, Slough SL1 3XE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalya","family":"Danchenko","sequence":"additional","affiliation":[{"name":"Ipsen, 92100 Boulogne-Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3469-7261","authenticated-orcid":false,"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[{"name":"Ipsen, 92100 Boulogne-Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Davis","sequence":"additional","affiliation":[{"name":"Ipsen, 92100 Boulogne-Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5288-4289","authenticated-orcid":false,"given":"Emanuel","family":"Engmann","sequence":"additional","affiliation":[{"name":"Ipsen, Slough SL1 3XE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Guyon","sequence":"additional","affiliation":[{"name":"Ipsen, 92100 Boulogne-Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Lecanuet","sequence":"additional","affiliation":[{"name":"Ipsen, 92100 Boulogne-Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9393-3197","authenticated-orcid":false,"given":"John","family":"Whalen","sequence":"additional","affiliation":[{"name":"Ipsen, Slough SL1 3XE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09638280400014576","article-title":"Spasticity: Clinical perceptions, neurological realities and meaningful measurement","volume":"27","author":"Pandyan","year":"2005","journal-title":"Disabil. Rehabil."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e17928","DOI":"10.2196\/17928","article-title":"Perspective of an an international online patient and caregiver community on the burden of spasticity and impact of botulinum neurotoxin therapy: Survey study","volume":"6","author":"Patel","year":"2020","journal-title":"JMIR Public Health Surveill."},{"key":"ref_3","unstructured":"Royal College of Physicians, The British Society Of Rehabilitation Medicine, The Chartered Society of Physiotherapy, and Association of Chartered Physiotherapists in Neurology and the Royal College of Occupational Therapists (2018). Spasticity in Adults: Management Using Botulinum Toxin National Guidelines, Royal College of Physician. [2nd ed.]."},{"key":"ref_4","first-page":"6","article-title":"Spasticity treatment with botulinum toxin","volume":"53","author":"Ward","year":"2007","journal-title":"Turk. J. Phys. Med. Rehab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1000004","DOI":"10.2340\/20030711-1000004","article-title":"Improving the management of post-stroke spasticity: Time for action","volume":"1","author":"Christofi","year":"2018","journal-title":"J. Rehabil. Med. Clin. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11795735211036576","DOI":"10.1177\/11795735211036576","article-title":"Early identification, intervention and management of post-stroke spasticity: Expert consensus recommendations","volume":"13","author":"Bavikatte","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","article-title":"A review of spasticity treatments: Pharmacological and interventional approaches","volume":"25","author":"Chang","year":"2013","journal-title":"Crit. Rev. Phys. Rehabil. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"jrm00157","DOI":"10.2340\/16501977-2801","article-title":"Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study","volume":"53","author":"Jacinto","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"jrm00133","DOI":"10.2340\/16501977-2770","article-title":"Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study","volume":"53","author":"Jacinto","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106889","DOI":"10.1016\/j.clineuro.2021.106889","article-title":"Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions","volume":"209","author":"Ozer","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_12","unstructured":"Ipsen Ltd (2023, March 01). Summary of Product Characteristics, Dysport\u00ae. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/964\/smpc."},{"key":"ref_13","unstructured":"AbbVie Ltd (2023, March 01). Summary of Product Characteristics, BOTOX\u00ae (onabotulinumtoxinA). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/859\/smpc."},{"key":"ref_14","unstructured":"Merz Pharma UK Ltd (2023, March 01). Summary of Product Characteristics, Xeomin\u00ae (incobotulinumtoxinA). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/6202\/smpc."},{"key":"ref_15","first-page":"97","article-title":"Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: Comparison of two preparations in 19 countries","volume":"5","author":"Roze","year":"2012","journal-title":"Med. Devices"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/13696998.2021.1957582","article-title":"Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: A systematic literature review, indirect treatment comparison, and economic evaluation","volume":"24","author":"Danchenko","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/13696998.2022.2092354","article-title":"The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia","volume":"25","author":"Danchenko","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/CEOR.S86355","article-title":"AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: A budget impact analysis","volume":"7","author":"Abogunrin","year":"2015","journal-title":"Clinicoecon. Outcomes Res"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"jrm00134","DOI":"10.2340\/16501977-2753","article-title":"A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus","volume":"53","author":"Francisco","year":"2021","journal-title":"J. Rehabil. Med."},{"key":"ref_20","unstructured":"Pohar, R., and Rabb, D. (2018). Switching Botulinum Toxin A Products for Patients with Upper Limb Spasticity Or cervical Dystonia: A Review of Clinical Effectiveness, CADTH Rapid Response Report: Summary with Critical Appraisal."},{"key":"ref_21","first-page":"43","article-title":"Duration of action of abobotulinumtoxinA and onabotulinumtoxinA. A randomized, double-blind study using a contralateral frontalis model","volume":"4","author":"Nestor","year":"2011","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamafacial.2017.1393","article-title":"Effect of 3 commercially available botulinum toxin neuromodulators on facial synkinesis: A randomized clinical trial","volume":"20","author":"Thomas","year":"2018","journal-title":"JAMA Facial Plast. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Khan, P., Riberto, M., Frances, J.A., Chueire, R., Amorim, A., Xerez, D., Chung, T.M., Mercuri, L.H.C., Longo, A.L., and Lianza, S. (2020). The effectiveness of botulinum toxin type A (BoNT-A) treatment in Brazilian patients with chronic post-stroke spasticity: Results from the observational, multicenter, prospective BCause study. Toxins, 12.","DOI":"10.3390\/toxins12120770"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.11604\/pamj.2020.35.55.16091","article-title":"Efficacy of botulinum toxin A for the treatment of hemiparesis in adults with chronic upper limb spasticity","volume":"35","author":"Ghroubi","year":"2020","journal-title":"Pan Afr. Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Field, M., Splevins, A., Picaut, P., van der Schans, M., Langenberg, J., Noort, D., Snyder, D., and Foster, K. (2018). AbobotulinumtoxinA (Dysport\u00ae), onabotulinumtoxinA (Botox\u00ae), and incobotulinumtoxinA (Xeomin\u00ae) neurotoxin content and potential implications for duration of response in patients. Toxins, 10.","DOI":"10.3390\/toxins10120535"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"576117","DOI":"10.3389\/fneur.2020.576117","article-title":"Duration of symptom relief between injections for abobotulinumtoxinA (Dysport\u00ae) in spastic paresis and cervical dystonia: Comparison of evidence from clinical studies","volume":"11","author":"Esquenazi","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_27","first-page":"S16","article-title":"Extensor digitorum brevis and DIRECTION: Two studies in progress comparing the duration of response of abobotulinumtoxina with other native botulinum toxins","volume":"214","author":"Esquenazi","year":"2022","journal-title":"Toxicon"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12955-020-01304-4","article-title":"Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA","volume":"18","author":"Fheodoroff","year":"2020","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11167","DOI":"10.1038\/s41598-023-38406-0","article-title":"Neuromuscular compartmentation of the subscapularis muscle and its clinical implication for botulinum neurotoxin injection","volume":"13","author":"Cho","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00276-023-03178-9","article-title":"Guidance in botulinum neurotoxin injection for lower extremity spasticity: Sihler\u2019s staining technique","volume":"45","author":"Hu","year":"2023","journal-title":"Surg. Radiol. Anat."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Yi, K.H., Lee, J.H., Hur, H.W., Lee, H.J., Choi, Y.J., and Kim, H.J. (Clin. Anat., 2023). Distribution of the intramuscular innervation of the triceps brachii: Clinical importance in the treatment of spasticity with botulinum neurotoxin, Clin. Anat., online ahead of print.","DOI":"10.1002\/ca.24004"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF01530764","article-title":"Goal attainment scaling: A general method for evaluating comprehensive community mental health programs","volume":"4","author":"Kiresuk","year":"1968","journal-title":"Community Ment. Health J."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/532\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:42:23Z","timestamp":1760128943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["toxins15090532"],"URL":"https:\/\/doi.org\/10.3390\/toxins15090532","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}